Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2010-05-30 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Exercise of Employee Options 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules (2.7, 3.10.3, 3.10.4, 3.10.5). It details the issuance of fully paid ordinary shares upon exercise of options under the Pharmaxis Ltd Employee Option Plan, including number of securities, classes, exercise prices, and dates. It also includes a quotation agreement with ASX and warranties related to the securities issuance. The document is a formal announcement of new securities issued and application for quotation on the ASX, consistent with Appendix 3B filings used in Australian markets for new share issues. It does not contain financial statements or detailed financial analysis, but rather focuses on capital changes and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP).
2010-05-30 English
Sustained Benefit Following 18 Month Bronchitol Treatment 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a media release dated 17 May 2010 announcing significant clinical trial results for Pharmaxis' drug Bronchitol in cystic fibrosis patients. It contains detailed clinical trial data, including lung function improvements and adverse events, but it is presented as a press/media release rather than a formal financial or regulatory report. There is no indication that this is an earnings release, annual or interim report, or any regulatory filing. It is a public announcement of clinical trial results and company news, typical of a press release. Therefore, it does not fit into categories like ER, 10-K, IR, or RNS. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2010-05-16 English
Appendix 3B - Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including number of securities, exercise prices, and terms. The document is a formal announcement to the ASX regarding the new issue of shares and application for quotation of additional securities. It does not contain financial statements or management discussion but is a regulatory filing specifically about capital changes. This matches the definition of a Share Issue/Capital Change announcement (SHA). The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2010-04-29 English
Pharmaxis resubmission for Aridol US marketing application 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 27 April 2010 from Pharmaxis announcing the FDA's acknowledgment of the resubmission of a New Drug Application (NDA) for Aridol. It is a public announcement about regulatory progress related to a drug application, not a financial report, earnings release, or detailed investor presentation. The document is relatively short (3743 characters) and serves as a news update rather than a detailed report or filing. It does not contain financial statements, management discussion, or regulatory certifications. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2010-04-26 English
Appendix 3B - Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including number of securities, terms, and quotation application. The document is a formal announcement of a new issue of shares and application for quotation on the ASX, consistent with Appendix 3B filings used in Australian markets for new share issues. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an announcement related to capital changes, specifically new share issuance and quotation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence classification.
2010-04-22 English
Change in substantial holding 4 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in substantial shareholdings, voting power, and relevant interests of a substantial holder in Pharmaxis Ltd. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a financial report, management information, or any other type of report but a regulatory notice about shareholding changes.
2010-04-21 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.